Skip to content

Ketamine research published in 2026

Page 4 of 35: studies 61 to 80 of 700, newest first. Back to the ketamine overview

Studies

The K-Hole Collapse: A Systematic Review of Multi-Organ Somatotoxicity and Management Strategies in Chronic Ketamine Misuse

Quality in Sport September 18, 2026 Wiktoria Podlasiewicz, Aleksandra Majewska, Leon Miller et al.

Ketamine is a psychoactive substance and an N-methyl-D-aspartate (NMDA) receptor antagonist, commonly used in anesthesiology, psychiatry, and emergency medicine. Its unique dissociative properties have led to a significant global increase in recreational misuse, particularly among young adults in nightlife environments. While the medical applications of ketamine demonstrate a favorable safety...

Neuroprotective potential of chrysin against ketamine-induced neurotoxicity: Effects on behavioral changes, oxidative stress, and neuroinflammation.

Neurotoxicology and Teratology September 18, 2026 Onur Karaca, Özge Kandemir, Hasan Şimşek et al.

Aim: Ketamine (KTM) is widely used in clinical settings for its anesthetic, analgesic, and antidepressant properties. However, prolonged or repeated KTM exposure can induce neurotoxicity through oxidative stress, neuroinflammation, and apoptotic mechanisms. This study investigated the neuroprotective effects of Chrysin (CHR), a natural flavonoid with potent antioxidant and anti-inflammatory...

DOI: 10.1016/j.ntt.2026.107720 (opens in new tab) Ketamine Oxidative stress Neurotoxicity Neuroinflammation +1

Samm50 Downregulation-Driven Mitochondrial Dysfunction Triggers Ferroptosis and Contributes to Ketamine-Induced Neurotoxicity and Cognitive Impairment.

Neuropharmacology September 18, 2026 Yuanlong Li, Xiangyun Dai, Junmei Hu et al.

Ketamine abuse is associated with persistent cognitive deficits and neurotoxicity, though the underlying mechanisms remain incompletely understood. While mitochondrial dysfunction and ferroptosis have been separately implicated, their causal relationship and the key molecular link in ketamine-induced hippocampal damage are unclear. Using a mouse model of ketamine-induced cognitive impairment...

DOI: 10.1016/j.neuropharm.2026.111192 (opens in new tab) Full text (opens in new tab) Ketamine Cognitive impairment Ferroptosis Hippocampal neurotoxicity +2

Ketamine metabolite HNK ameliorates anhedonia symptom in Alzheimer's disease mice.

Biochemical and Biophysical Research Communications September 17, 2026 Shuo Yang, Baihong Guo, Di Deng et al.

Anhedonia is frequently observed in Alzheimer's disease (AD) patients and is associated with a higher risk of cognitive decline and dementia, and it potentially serve as preclinical marker and psychopathological risk factor for AD. Current antidepressants show limited efficacy in anhedonia, highlighting a critical unmet medical need. In this study, APP/PS1 mice at 8 months of age exhibited...

DOI: 10.1016/j.bbrc.2026.154535 (opens in new tab) Full text (opens in new tab) Alzheimer's disease Anhedonia Excitatory/inhibitory ratio Sucrose preference test

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review

Psychiatry Research Neuroimaging September 17, 2026 Juliana Lima Constantino, Jesca E. de Jager, Jasper O. Nuninga et al.

Antidepressant treatments, including conventional antidepressants and (es)ketamine, may reverse default mode network (DMN) resting-state functional connectivity (rsFC) alterations related to major depressive disorder (MDD). Despite these agents having distinct initial action mechanisms, both likely share downstream effects that lead to structural and functional adaptations in MDD-related neural...

Esketamine for treatment of depression in Huntington's disease: A case report

Journal of Huntington's Disease September 17, 2026 Carsten Saft, Julia Jessen, David Kiefner et al.

Depression and suicidal ideation are common in Huntington's disease (HD). We report a 60-year-old male with HD who suffered from treatment-resistant depression with intermittent suicidal thoughts for 20 years, irritability and apathy. Despite multiple trials of antidepressants, no sustained improvement was achieved. Under nasal esketamine treatment his mood improved dramatically after three...

[Intravenous ketamine in suicidal crisis : indications and patient referral].

Revue Médicale Suisse September 16, 2026 Rayan Nasserdine, Laura Xhymshiti, Anne-Charlotte Paporé et al.

Intravenous (IV) ketamine is a rapidly acting therapeutic option for the management of treatment-resistant depression and acute suicidal crisis. Unlike conventional antidepressants, its effects may occur within hours, allowing a rapid reduction in suicidal ideation and psychological distress. Its use remains specialized and requires hospital-based care with medical monitoring and a...

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.

Psychiatry Research September 14, 2026 Kelei Xiao, Yealin Woo, Christine E. Dri et al.

Cognitive impairment is a core feature of major depressive disorder (MDD) and bipolar disorder (BD). Most conventional antidepressants do not have direct and clinically relevant procognitive effects. Ketamine and esketamine are effective in treating treatment-resistant depression (TRD). Herein, this systematic review aims to evaluate the effects of both pharmacotherapeutics on cognitive...

Correlation of Ketamine and Classic Psychedelics with Pain-Related Neural Connectivity: A Scoping Review of Clinical Experiments on a Potential Therapeutic Target Concerning Ketamine and Classical Psychedelics Administration for Pain Relief

Psychedelic Medicine September 14, 2026 Vasileios Chytas, Georgios Tsimploulis, Dimitrios Chytas

Purpose: Ketamine and classic psychedelics have recently gained increased scientific interest regarding their role in pain management, while there is evidence that pain induces neural connectivity changes. We performed a scoping review to investigate the correlation of ketamine and classic psychedelics with pain-related neural connectivity, aiming to find potential therapeutic targets for these...

At-Home Racemic Ketamine Treatment: A Structured Framework for Preparation, Route-Specific Dosing, Monitoring, Rescue, Recovery, and Follow-Up

International Journal of Independent Research Studies September 11, 2026 Eric P. Rubenstein

Ketamine is increasingly used in psychiatric and psychotherapeutic treatment through intravenous, intranasal, sublingual or buccal, and subcutaneous administration. Its therapeutic applications extend beyond formally diagnosed psychiatric disorders and include existential anxiety, persistent emotional distress, trauma-related suffering, psychological responses to serious illness or major life...

EFFECTS OF KETAMINE AND ESKETAMINE ON SUICIDAL IDEATION WITHIN THE FIRST 24 HOURS IN ADULTS WITH DEPRESSIVE DISORDERS: VARIABILITY IN CLINICAL FINDINGS AND INTERPRETATIVE CHALLENGES - A NARRATIVE REVIEW

International Journal of Innovative Technologies in Social Science September 11, 2026 Marta Borkowska, Małgorzata Witaszczyk, Alicja Sołtan et al.

Background: Ketamine and esketamine have been studied as rapid-acting interventions in adults with depressive disorders and suicidal ideation, but findings vary across populations, settings, comparators, routes, and outcome measures. Aim: To examine their effects on suicidal ideation within the first 24 hours and to identify factors contributing to variability across studies. Methods: This...

Chronic sensing during subcallosal cingulate deep brain stimulation captures ketamine-associated changes in major depressive disorder

medRxiv September 11, 2026 Srdjan Sumarac, Tristan Lawson, Leonardo Favi Bocca et al. preprint

Ketamine and subcallosal cingulate (SCC) deep brain stimulation (DBS) have each shown antidepressant effects in treatment-resistant depression, yet how ketamine modulates SCC physiology during chronic stimulation remains poorly understood. We analyzed 5,907 hours of bilateral SCC sensing, 485 participant-triggered recordings across 193 days, 47 ketamine dosing episodes, and an in-clinic...

Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients.

Journal of Psychiatric Research September 10, 2026

Background: Major depressive and bipolar disorders are leading causes of disability, with many patients developing treatment-resistant depression (TRD/TRBD). Ketamine offers rapid symptom relief, yet recovery extends beyond symptoms. Life engagement (LE) is a key patient-centered outcome encompassing the ability to experience pleasure, function effectively, and participate in meaningful...

Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder with Comorbid Treatment-Resistant Depression: A Six-Month Case Report

Psychiatry International September 10, 2026 Tommaso Barlattani, Giorgio Sernia, Chiara D’Amelio et al.

Background: Evidence for repeated intranasal esketamine in obsessive–compulsive disorder (OCD) remains preliminary, particularly when OCD co-occurs with treatment-resistant depression (TRD). Methods: We report a 58-year-old woman treated with intranasal esketamine in routine clinical care for TRD; change in obsessive–compulsive symptoms was followed as a secondary observational outcome. Her...

457. Intensive longitudinal monitoring of symptoms in response to treatment with intranasal esketamine

The International Journal of Neuropsychopharmacology September 9, 2026 M Saje, Jurij Bon, Aleš Oblak

Abstract Background Esketamine is a NMDA receptor antagonist that has been approved as treatment for treatment-resistant depression (TRD). Unlike serotoninergic therapies requiring weeks for effect, intranasal esketamine modulates glutamate neurotransmission, often yielding symptom relief within hours and significant response rates within one month [1]. This rapid action is particularly...

716. A randomised-controlled feasibility study of ketamine for the treatment of depression with anorexia nervosa

The International Journal of Neuropsychopharmacology September 9, 2026 Johanna Keeler, Hubertus Himmerich, Janet Treasure et al.

Abstract Background Approximately a third of people with anorexia nervosa (AN) develop a severe and enduring form of the illness, which is often accompanied by depression. This can be a key barrier to recovery. Anti-depressant medications are less effective in treating depression in patients with acute AN, thus new pharmacological treatment options are needed. Ketamine is currently used for...

301. Multimodal MRI signatures predict ketamine antidepressant response in treatment-resistant depression: a machine-learning analysis of independent clinical trials

The International Journal of Neuropsychopharmacology September 9, 2026 P-C Wu, T-P Su, C-T Li et al.

Abstract Background While ketamine produces rapid antidepressant effects in treatment-resistant depression (TRD), response heterogeneity necessitates robust biomarkers to optimize clinical decision-making. Aims & Objectives To validate a machine-learning (ML) framework for predicting ketamine antidepressant response from pre-treatment multimodal neuroimaging features across independent...

286. Restoration by ketamine metabolites of cognitive and affective prosocial behaviors in a mouse model of depression

The International Journal of Neuropsychopharmacology September 9, 2026 Rei Yokoyama, M Matsumi, S Asano et al.

Abstract Background The execution of prosocial behaviors requires the ability to accurately understand and infer others’ affective states. Impairments in prosocial functioning have been shown to be associated with the pathology of several psychiatric disorders. In particular, individuals with depression exhibit reduced cognitive and affective responses to others’ emotions. These impairments may...

507. Ketamine use disorder following intranasal esketamine for treatment-resistant depression: a case report and literature review

The International Journal of Neuropsychopharmacology September 9, 2026 Y-H Chan, H-M Chang

Abstract Background Esketamine, the S-enantiomer of ketamine, is an NMDA receptor antagonist approved for treatment-resistant depression (TRD). Although regulated clinical trials suggest a low risk of misuse, concerns remain that esketamine exposure may facilitate transition to ketamine dependence, particularly in East Asia where illicit ketamine is widely available. Aims & Objectives To...

Ketamine-Induced Dissociation as an Ethical Signal, Not a Side Effect: Context as the Determinant of Clinical Duties Under Beneficence and Non-maleficence

HEC Forum September 9, 2026 Gun Moon, Jack Noto, Zachary Shuler et al.

Ketamine has emerged as an important intervention in contemporary psychiatry, yet its acute dissociative effects remain ethically under-theorized. Clinical approaches often frame dissociation as either a liability to minimize or a therapeutic feature to promote, but both views oversimplify a context-dependent phenomenon. We propose that ketamine-induced dissociation is better understood as an...